Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 2/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 2/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 10/20 | 0.69 |
| ▸ | ABCG2 | Q9UNQ0 | 10/20 | 0.69 |
| ▸ | ABCC1 | P33527 | 9/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | THPO | P40225 | 2/20 | 0.66 |
| ▸ | MTOR | P42345 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.64 |
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexobendine SCHEMBL2459088 | 0.99 | SCN1A (0.97) | SCN1ASCN2ASCN3AABCB1ABCG2 | |
| Hexobendine SCHEMBL10402178 | 0.99 | SCN1A (0.97) | SCN1ASCN2ASCN3AABCB1ABCG2 | |
| Hexobendine SCHEMBL317378 | 0.99 | SCN1A (0.97) | SCN1ASCN2ASCN3AABCB1ABCG2 | |
| SCHEMBL2459622 | 0.90 | SCN1A (0.82) | SCN1ASCN2ASCN3AABCB1ABCG2 | |
| SCHEMBL2459994 | 0.87 | ABCB1 (0.92) | SCN1ASCN2ASCN3AABCB1ABCG2 | |
| SCHEMBL2459996 | 0.87 | ABCB1 (0.92) | SCN1ASCN2ASCN3AABCB1ABCG2 | |
| SCHEMBL25981898 | 0.86 | SCN1A (0.74) | SCN1ASCN2ASCN3AABCB1ABCG2 | |
| Hydrochloric Acid SCHEMBL7883012 | 0.83 | MEN1 (0.77) | SCN1ASCN2ASCN3AABCB1ABCG2 | |
| Dilazep SCHEMBL11130839 | 0.83 | SLC29A1 (0.77) | SCN1ASCN2ASCN3AABCB1ABCG2 | |
| SCHEMBL11219537 | 0.82 | SCN1A (0.69) | SCN1ASCN2ASCN3AABCB1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1861 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11998001-B2 | Perfusion device for normothermic, ex vivo preservation of a mammalian brain | YALE UNIVERSITY (US) | 2024-06-04 | — | — | US | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| US-20230093487-A1 | VASODILATORS FOR TREATMENT OF HEART FAILURE | NORTHEAST OHIO MEDICAL UNIV (US) | 2023-03-23 | — | — | US | claimed |
| US-11534375-B2 | Solvent-free method of encapsulating a hydrophobic active | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-12-27 | — | — | US | claimed |
| US-11324748-B2 | Vasodilators for treatment of heart failure | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2022-05-10 | — | — | US | claimed |
| US-20210360913-A1 | METHODS, SYSTEMS AND COMPOSITIONS FOR NORMOTHERMIC EX VIVO PRESERVATION OF INTACT ORGANS | UNIV YALE (US) | 2021-11-25 | — | — | US | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| EP-3749091-A1 | METHODS, SYSTEMS AND COMPOSITIONS FOR NORMOTHERMIC EX VIVO RESTORATION AND PRESERVATION OF INTACT ORGANS | Yale University (US) | 2020-12-16 | — | — | EP | claimed |
| US-20200179248-A1 | SOLVENT-FREE METHOD OF ENCAPSULATING A HYDROPHOBIC ACTIVE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-06-11 | — | — | US | claimed |
| US-20190282580-A1 | PRO-INFLAMMATORY ROLE FOR ADENOSINE UPTAKE AND METABOLISM | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY | 2019-09-19 | — | — | US | claimed |
| US-5567689-A | CONCURRENT ADMINISTERING MIXTURE OF URIDINE PHOSPHORYLASE INHIBITOR, URIDINE SECRETION INHIBITOR AND(OR) COMPOUNDWHICH COMPETES WITH URIDINE IN RENAL TRANSPORTATION MECHANISM | THE UAB RESEARCH FOUNDATION (US) | 1996-10-22 | — | — | US | claimed |
| EP-0716603-A1 | METHODS AND COMPOSITIONS FOR INHIBITING URIDINE SECRETION | THE UAB RESEARCH FOUNDATION (US) | 1996-06-19 | — | — | EP | claimed |
| EP-0687172-A1 | SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF | Pharmacia & Upjohn Aktiebolag (SE) | 1995-12-20 | — | — | EP | claimed |
| WO-1995005180-A1 | METHODS AND COMPOSITIONS FOR INHIBITING URIDINE SECRETION | THE UAB RESEARCH FOUNDATION (US) | 1995-02-23 | — | — | WO | claimed |
| WO-1994020072-A1 | SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF | PHARMACIA AB (SE) | 1994-09-15 | — | — | WO | claimed |
| EP-0594223-A1 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-04-27 | — | — | EP | claimed |
| EP-0416011-A4 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | US COMMERCE (US) | 1991-05-22 | — | — | EP | claimed |
| EP-0416011-A1 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1991-03-13 | — | — | EP | claimed |
| WO-1989011274-A1 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 1989-11-30 | — | — | WO | claimed |
| EP-0217580-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-04-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230093487-A1 | VASODILATORS FOR TREATMENT OF HEART FAILURE | VASP, TNNI3, EDNRB | SCN1A 2054/4885SCN2A 1529/4885SCN3A 1087/4885 |
| US-11324748-B2 | Vasodilators for treatment of heart failure | VASP, TNNI3, EDNRB | SCN1A 2054/4885SCN2A 1529/4885SCN3A 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.